Differences in nasal immunoglobulin A responses to influenza vaccine strains after live attenuated influenza vaccine (LAIV) immunization in children.
Adolescent
Antibodies, Viral
/ immunology
Child
Child, Preschool
Female
Humans
Immunization
Immunoglobulin A
/ immunology
Influenza A Virus, H1N1 Subtype
/ immunology
Influenza A Virus, H3N2 Subtype
/ immunology
Influenza Vaccines
/ administration & dosage
Male
Nasal Cavity
/ immunology
Vaccines, Live, Unattenuated
/ administration & dosage
children
influenza
nasal
public health
vaccine
Journal
Clinical and experimental immunology
ISSN: 1365-2249
Titre abrégé: Clin Exp Immunol
Pays: England
ID NLM: 0057202
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
accepted:
24
10
2019
pubmed:
2
11
2019
medline:
22
7
2020
entrez:
1
11
2019
Statut:
ppublish
Résumé
Different vaccine strains included in the live attenuated influenza vaccine (LAIV) have variable efficacy. The reasons for this are not clear and may include differences in immunogenicity. We report a Phase IV open-label study on the immunogenicity of a single dose of quadrivalent LAIV (Fluenz™ Tetra) in children during the 2015/16 season, to investigate the antibody responses to different strains. Eligible children were enrolled to receive LAIV; nasal samples were collected before and approximately 4 weeks after immunization. There was a significant increase in nasal immunoglobulin (Ig)A to the H3N2, B/Victoria lineage (B/Brisbane) and B/Yamagata lineage (B/Phuket) components, but not to the H1N1 component. The fold change in nasal IgA response was inversely proportional to the baseline nasal IgA titre for H1N1, H3N2 and B/Brisbane. We investigated possible associations that may explain baseline nasal IgA, including age and prior vaccination status, but found different patterns for different antigens, suggesting that the response is multi-factorial. Overall, we observed differences in immune responses to different viral strains included in the vaccine; the reasons for this require further investigation.
Identifiants
pubmed: 31670841
doi: 10.1111/cei.13395
pmc: PMC6954673
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin A
0
Influenza Vaccines
0
Vaccines, Live, Unattenuated
0
Types de publication
Clinical Trial, Phase IV
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
109-118Subventions
Organisme : Medical Research Council
ID : MR/K010468/1
Pays : United Kingdom
Informations de copyright
© 2019 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society for Immunology.
Références
Arch Dis Child. 2018 Jan;103(1):101-105
pubmed: 28855230
Vaccine. 2016 Sep 30;34(42):5066-5072
pubmed: 27613072
MMWR Recomm Rep. 2017 Aug 25;66(2):1-20
pubmed: 28841201
J Infect Dis. 2000 Mar;181(3):1133-7
pubmed: 10720541
Front Microbiol. 2017 May 17;8:900
pubmed: 28567036
Evolution (N Y). 2011 Dec;4(4):635-643
pubmed: 22468165
Methods Mol Biol. 2012;865:147-62
pubmed: 22528158
Vaccine. 2012 Nov 6;30(48):6794-801
pubmed: 23000125
Philos Trans R Soc Lond B Biol Sci. 2013 Jun 24;368(1623):20120140
pubmed: 23798688
mBio. 2011 Jan 25;2(1):e00309-10
pubmed: 21264063
Influenza Other Respir Viruses. 2018 Jan;12(1):3-9
pubmed: 29460425
J Infect Dis. 2016 May 15;213(10):1546-56
pubmed: 26743842
BMC Med. 2017 Sep 8;15(1):166
pubmed: 28882149
Vaccine. 2018 May 17;36(21):3034-3040
pubmed: 29680198
Pediatrics. 2016 Feb;137(2):e20153279
pubmed: 26738884
Clin Infect Dis. 2012 Oct;55(7):951-9
pubmed: 22843783
Clin Infect Dis. 2014 Jan;58(2):181-7
pubmed: 24149079
J Infect Dis. 2009 Jan 15;199(2):159-67
pubmed: 19086915
J Immunol Methods. 2017 Oct;449:1-6
pubmed: 28647455
Euro Surveill. 2016 Sep 22;21(38):
pubmed: 27684603
Euro Surveill. 2018 Jun;23(25):
pubmed: 29945698
MMWR Recomm Rep. 2018 Aug 24;67(3):1-20
pubmed: 30141464
Lancet Infect Dis. 2018 Jan;18(1):e25-e32
pubmed: 28780285
Euro Surveill. 2017 Nov;22(44):null
pubmed: 29113630